Ignite Creation Date:
2024-05-05 @ 11:28 AM
Last Modification Date:
2024-10-26 @ 9:08 AM
Study NCT ID:
NCT00050999
Status:
COMPLETED
Last Update Posted:
2008-03-05
First Post:
2002-12-31
Brief Title:
Study of ONTAK Denileukin Diftitox in Cutaneous T-Cell Lymphoma CTCL Patients
Sponsor:
Eisai Inc
Organization:
Eisai Inc
Study Overview
Official Title:
A Multicenter Phase III Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy of Two Dose Levels of DAB389IL-2 9 and 18 McgkgDay in Cutaneous T-Cell Lymphoma CTCL Patients With Stage Ia-III Disease Who Following Less Than or Equal to 3 Previous Therapies Have Recurrent or Persistent Disease That Has Been Biopsy-Documented to Express CD25
Status:
COMPLETED
Status Verified Date:
2008-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to compare the effectiveness of two dose levels of ONTAK denileukin diftitox in treating patients who have recurrent or persistent cutaneous T-cell lymphoma
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None